research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
Search
for
Sort by
Research
390-420 / 1000+ results research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Oral Tofacitinib in Refractory Pediatric Alopecia Areata
Oral tofacitinib may effectively regrow hair in children with alopecia areata unresponsive to other treatments.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production
The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
research Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
research Efficacy and Safety of Combination 308-nm Excimer Laser and Intralesional Corticosteroid versus Intralesional Corticosteroid Monotherapy in the Treatment of Frontal Fibrosing Alopecia: A Pilot Study
Combining laser and corticosteroid is not better than corticosteroid alone for treating frontal fibrosing alopecia.
research Frontal fibrosing alopecia
Frontal fibrosing alopecia causes hair loss at the front hairline, and no effective treatment exists.
research Combination tofacitinib and oral minoxidil treatment for severe alopecia areata
Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
research Successful treatment of frontal fibrosing alopecia with alitretinoin
Alitretinoin can effectively treat frontal fibrosing alopecia.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays
The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
This post hoc analysis of the ALLEGRO phase 2b/3 study evaluated the efficacy of ritlecitinib, an oral JAK3/TEC inhibitor, in patients with alopecia areata (AA) who did not meet target efficacy response criteria at Week 24. The study included patients aged 2-12 years with at least 50% scalp hair loss. Results showed that among those who did not respond by Week 24, 8-14% achieved a response by Week 28, increasing to 22-34% by Week 48. Similar improvements were observed for eyebrow and eyelash assessments. Ritlecitinib was well tolerated, with common adverse events including upper respiratory tract infection, nasopharyngitis, and headache. The findings suggest that continued ritlecitinib treatment may lead to hair regrowth in patients who initially do not respond.
research Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review
Leflunomide can cause severe hair loss in some rheumatoid arthritis patients.
research Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?
Low-dose naltrexone might be a cheap and effective additional treatment for hair loss with scalp discomfort due to its anti-inflammatory effects and few side effects.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series
Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-α-Reductase in the Treatment of Androgenetic Alopecia
Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
research LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research FINASTERIDE AND PSA
research Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database
Sonidegib and vismodegib have different side effects and reporting patterns.
research Repurposing With Purpose: Treatment of Bachmann–Bupp Syndrome With Eflornithine and Implications for Other Polyaminopathies
Eflornithine improved symptoms in Bachmann–Bupp Syndrome patients.
research Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study
Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research In Silico Screening of DrugBank Compounds as Potential Inhibitors for Human Steroid 5α-Reductase 2 for Androgen-Related Diseases
Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.